DNA-Encoded Library Screening Identifies CDK2-Targeting Lead Compounds with Favorable Drug-like Properties for Anticancer Development

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Journal of Pharmaceutical Analysis

• Publication date

  2025-11-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/j.jpha.2025.101498
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• New insights into the dule roles CDK12 in human cancers: Mechanisms and interventions for cancer therapy

  2024cited by this paper
• A narrative review about CDK4/6 inhibitors in the setting of drug resistance: updates on biomarkers and therapeutic strategies in breast cancer

  2023cited by this paper
• A patent review of anticancer CDK2 inhibitors (2017–present)

  2022cited by this paper
• Targeting CDK2 in cancer: challenges and opportunities for therapy.

  2019cited by this paper
• Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response

  2017cited by this paper

• No citing papers are available for this paper.